If the Food and Drug Administration authorizes use of the drug, called molnupiravir, it would be the first oral COVID-19 treatment that could be taken at home.
More than 100 pharmaceutical drugs are currently in short supply across the country — many of those life-saving. With the crunch on the nation’s supply chain, advocates are worried about the impact on chronically ill patients who rely on their prescriptions to survive.
A plaque-busting Alzheimer's drug called Aduhelm has yet to prove it can preserve memory and thinking. Even so, its approval by the Food and Drug Administration is making some patients opitimistic.
An experimental medicine seems to ease symptoms of Fragile X syndrome, a genetic disorder that is the most common inherited cause of intellectual disabilities and autism.
Drugs that can help keep COVID-19 patients out of the hospital are playing only a small role in Michigan, where the pandemic is accelerating. Logistical challenges are to blame.
Drugs for COVID-19 are sorted into three basic categories: They work, they don't work, or there simply isn't enough information to know. A generic steroid is one medicine that proved helpful.
A newly approved drug can extend the lives of children with progeria, a rare disorder that causes rapid aging. The drug is the result of one family's effort to help a child with the fatal condition.
Amazon launches an online pharmacy, sending shares of CVS, Walgreens and Rite Aid tumbling. Amazon has pushed to compete with Walmart and major pharmacy chains that have long offered home delivery.
Eli Lilly's monoclonal antibody will be available to people 65 or older or those with underlying health conditions. Supplies will be short, and allocating the medicine will be a challenge.
To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing.
Experimental medicines have the potential to help people with COVID-19 avoid hospitalization. The scarce supply of the treatments would have to be rationed, if regulators OK their use.
Drugs are being tested that could reduce symptoms and save lives. But, given the way drugs are developed, it's unlikely that any single medicine will be anywhere as potent as a successful vaccine.
AstraZeneca, which is working with the University of Oxford, hasn't said what the illness is. It will try to determine whether the illness is related to the vaccine, or just a chance event.
